Background {#Sec1}
==========

The malaria parasite *Plasmodium falciparum* is one of the major causes of morbidity and mortality in sub-Saharan African countries, especially in children and pregnant women. Many factors have contributed to the development and spread of drug resistance, including gene mutations and drug pressure \[[@CR1]\]. Resistance to chloroquine (CQ), the most widely used and affordable antimalarial drug, has contributed to the increased in mortality and morbidity caused by *P. falciparum* infections in endemic areas \[[@CR2]\]. Resistance to chloroquine, the cheapest and most widely available anti-malarial, has reached significantly high levels leading to replacement with artemisinin-based combination therapy (ACT) in many malaria-endemic countries \[[@CR3]\].

Molecular genotyping and characterization of mutations for single nucleotide polymorphism (SNPs) have been used for drug resistance monitoring and could predict emerging or existing drug resistance patterns. Genetically, chloroquine and amodiaquine resistance has been linked to *P. falciparum* chloroquine resistance transporter (*Pfcrt*) gene from different parts of the world \[[@CR4]-[@CR7]\], as well as mutations in *P. falciparum* multidrug resistance 1 (*Pfmdr1*) \[[@CR8],[@CR9]\].

Polymorphisms in the *Pfmdr*1 gene have been shown by transfection to modulate higher levels of chloroquine resistance and to affect mefloquine, halofantrine, and quinine resistance \[[@CR10]-[@CR12]\]. The role played by *Pfmdr1* mutations (N86Y, Y184F, S1034C and D1246Y) in mediating *in vivo* and *in vitro* chloroquine resistance has received a lot of research interest \[[@CR13]-[@CR15]\]. It has been reported that mutations in the region of *Pfcrt* encompassing codons 72 -- 76 is a key marker of *P. falciparum* chloroquine resistance \[[@CR16]\]. Substitutions in the wild type allele, encoding CVMNK, give rise to several resistant variants, of which the most common are CVIET in South-East Asia and Africa and SVMNT, which has been reported in South America \[[@CR4]\] and Asia \[[@CR17]\], but rarely in Africa \[[@CR18]\]. The change in single codon of *Pfcrt* gene from Lys (K) to Thr (T) at position 76 (K76T) thus is reported to play a decisive role in conferring resistance to chloroquine \[[@CR4]\]. Prolonged use of chloroquine monotherapy has imposed high selection pressure, leading to a substantial increase in the prevalence of this marker in parasite populations worldwide.

In Nigeria, despite the change in National malaria drug policy to ACT because of the widespread and high-level clinical failure rate of chloroquine, CQ is still widely used in the treatment of malaria in the country \[[@CR19]\], because it is accessible and affordable. Previous studies have reported resistance to chloroquine by a change at position 76 (K76T) in children treated with chloroquine in Lagos, just before the change in policy \[[@CR20]\], in Ibadan \[[@CR21]\] and in Osogbo \[[@CR22]\]. However, in the above studies, CQ was still the first-line antimalarial medicine before a change in policy to ACTs and the children were treated with chloroquine. The studies did not also provide expanded haplotype information on single nucleotide polymorphisms (SNPs). Therefore, this study was carried out to elucidate single nucleotide polymorphisms in *Pfcrt* and the point mutations in *Pfmdr1* genes with the aim of determining the status of CQ-resistant *Plasmodium falciparum* genes in a diverse and highly populated setting in Lagos, Nigeria, in the light of reports on return of CQ sensitive (wild type) parasites in Malawi and Kenya \[[@CR23],[@CR24]\] after the total removal of CQ from the population.

Methods {#Sec2}
=======

Study area/sites {#Sec3}
----------------

This study was conducted at the St. Kizito Primary Health Centre, Lekki, and Massey Street Children's Hospital Lagos Island, Lagos State, Southwestern Nigeria -- a holoendemic area for malaria. Massey children's clinic attends to outpatients and serves as a referral paediatric centre in Lagos Metropolis. Lagos State is a commercial area with a diverse population of over 20 million people drawn from other states of Nigeria and West Africa. Lagos is located between latitude and longitude; 6°35′N 3°20′E with an altitude of 40 m (131 ft). The average temperature is 26.4°C (80°F) while the range of average monthly temperatures is 29°C to 35°C. Mean relative humidity for an average year is recorded as 84.7% and on a monthly basis it ranges from 80% in March to 88% in June, July, September and October \[[@CR25]\].

Study population {#Sec4}
----------------

This research was part of a larger cross-sectional study on uncomplicated malaria in febrile children that was conducted between July 2007 and April 2008. Blood samples were collected through finger pricks from 1,211 febrile children (0--12 years) attending the outpatient clinics in both facilities. Thin and thick blood films were prepared and blood drops were spotted on Whatman filter papers. Parasite DNAs were extracted from a cohort of those that were positive by microscopy.

Malaria microscopy {#Sec5}
------------------

This was the first step needed to select the dry blood spots in filter paper for the genetic analysis. Consent was obtained from the Parents/Guardian of the children before they were enrolled. Briefly, thick and thin smears were made on the same slide for each child from finger prick using a sterile lancet. Two slides were made for each child. The first slide was the read "(R)" slide (that is the slide that was read), while the other slide was archived "(A)" slide. This is in line with the quality assurance process of the ANDI Centre of Excellence for Malaria Diagnosis, College of Medicine, University of Lagos to ascertain the children who were positive with *Plasmodium falciparum*. Standard malaria microscopy protocol was used in staining the prepared slides. Parasitaemia levels were obtained from thick smears by counting the number of asexual parasites against 500 leucocytes and expressed per micro liter of blood using an assumed leukocyte count of 8000 wbc/ul. All patients studied received appropriate standard of care after their blood was examined.

Extraction of DNA from samples collected on filter paper {#Sec6}
--------------------------------------------------------

Parasite genomic DNA was extracted from dried filterpapers using the Chelex®100 method according to methods described elsewhere \[[@CR26]\]. Briefly, the discs were lysed in 5% saponin in 1 × PBS and incubated at 37°C overnight. The samples were centrifuged, saponin and debris were removed using a vacuum pump, and the pellets washed twice in buffered saline. The samples were then suspended in 6% Chelex®100 resin and heat-sealed in deep 96-well plates. The samples were incubated in boiling water for 20--25 minutes and then centrifuged to remove resin. Approximately 100 μl of supernatant containing DNA was removed and stored at −20°C.

Genotyping of the *Pfcrt* locus using qPCR {#Sec7}
------------------------------------------

Double-labelled probes were designed to detecthaplotypes at codons 72 to 76 of the *Pfcrt* gene. Each probe was dual-labelled with a reporter dye at the 5′ end and a quencher moiety at the 3′ end. This method have been previously described using this assay for *Pfcrt* genotyping in the UK \[[@CR17],[@CR27],[@CR28]\]. Briefly, *Pfcrt* DNA was amplified from each sample using previously described conditions and the amplification primers *Pfcrt* F (TGG TAA ATG TGC TCA TGT GTT T) and *Pfcrt* R (AGT TTC GGA TGT TAC AAA ACT ATA GT) \[[@CR27]\]. Amplification was performed in a Corbett Rotorgene 3000 (Corbett, Sydney, Australia) in the presence of each of the three double-labelled probes, representing the wild-type and the two most common resistance-associated haplotypes at codons 72--76 of *Pfcrt*. The probes were crt76CVMNK wild-type, 5′FAM-TGT GTA ATG AAT AAA ATT TTT GCT AA-BHQ1 (3D7 DNA from MR4 used as a positive control); crt76CVIET resistant, 5′JOE-TGT GTA ATT GAA ACA ATT TTT GCT AA-BHQ1 (Dd2 DNA from MR4 used as a positive control); and crt76SVMNT resistant, 5′ROX-AGT GTA ATG AAT ACA ATT TTT GCT AA-BHQ2 (7G8 DNA from MR4 used as a positive control). The control parasite DNA was obtained directly from The Malaria Research and Reference Reagent Resource (MR4, Manassas, Vermont, USA). Samples were considered positive for a particular genotype if a CT (threshold cycle) value of 35 cycles or fewer was obtained in at least two independent PCR experiments. Nuclease-free water was included as a negative control.

*Pfmdr1* genotyping {#Sec8}
-------------------

Amplification of the *Pfmdr1* gene was performed in three fragments (FR1, FR3 and FR4). Primers and cycling conditions used for the three fragments are listed in Table [1](#Tab1){ref-type="table"}. These samples were amplified using Nested PCR reactions. In each reaction, appropriate known positive (Dd2, 7GB and FCR3) and negative samples (DNA negative wells on each row) were used.Table 1***Pfmdr1*** **PCR primer sequences and reaction conditions used in Fragments 1, 3 and 4 amplification reactionsGene fragmentPrimer namePrimer sequenceCodonsPCR cycling conditions**Fragment 1Primary FR1FN1/1F5′- AGGTTGAAAAAGAGTTGAAC-3′86, 18494°C 3 min/\[94°C 30 s-45°C 60 s 72°C 60 s\]REV/C1R5′- ATGACACCACAAACATAAAT-3′×30 cyclesNested FR1MDR2/1F5′- ACAAAAAGAGTACCGCTGAAT -3′72°C for 5 minutes/15°C 5 minNEWREV1R5′-AAACGCAAGTAATACATAAAGTC-3′Fragment 3Primary FR3MDRFR3N1F5′-GCATTTTATAATATGCATACTG-3′1034, 104294°C 3 min/\[94°C 30 s-55°C 60 s 65°C 40 s\]MDRFR3R1R5′-GGATTTCATAAAGTCATCAAC-3′×30 cyclesNested FR3MDRFR3N2F5′-GGTTTAGAAGATTATTTCTGTA-3′72°C 5 min/15°C 5 minMDRFR3R1R5′-GGATTTCATAAAGTCATCAAC-3′Fragment 4Primary FR4MDRFR4N1F5′- CAAACCAATCTGGATCTGCAGAAG -3′124694°C 3 min/\[94°C 30 s-55°C 60 s-65°C 40 s\]MDRFR4R1R5′-CAATGTTGCATCTTCTCTTCC -3′×30 cyclesNested FR4MDRFR4N2F5′- GATCTGCAGAAGATTATACTG -3′72°C 5 min/15°C 5 minMDRFR4R1R5′- CAATGTTGCATCTTCTCTTCC -3′FR - Fragment F - forward R - Reverse.NB: Cycling conditions are the same for primary and nested PCRs.

The *Pfmdr1* PCR products of nested reactions were separated by gel electrophoresis on a 1.2% agarose gel stained with ethidium bromide to identify amplified bands of DNA under ultra-violet illumination. Amplicons from nested PCR products were purified using ExoSap IT reaction \[[@CR29]\] and were sent for sequencing. Sequencing was performed using the BigDye 3.1, Cycle Sequencing Kit (Applied Biosystems, UK) using conditions and sequencing primer pairs described elsewhere \[[@CR26],[@CR30]\]. The sequence of amplified DNA products was determined using ABI PRISM 3730 Genetic Analyser (Applied Biosystems, UK). Chromas software (Technelysium, Australia) and was used to analyse the sequence results. The DNA sequence was compared with reference sequence of the *Pfmdr1*, portions of the *P. falciparum* 3D7 clone using BLAST similarity alignment (Washington University, USA). In each reaction, appropriate control DNA samples with known *Pfmdr1* sequences were used in parallel with field-collected parasite isolates in every step of the protocol.

Results {#Sec9}
=======

A total of 1,211 children were screened in this study. The children tested included 658 (54.4%) males and 553 (45.6%) females; mean age ± SD was 2.65 ± 2.83; while their mean body temperature was 37.8°C (range, 35.5--42°C). Out of the total children (*\<*12 years) tested, 251 (20.7%) were positive for malaria parasites by microscopy. Parasite DNAs were successfully obtained from a cohort of 251 microscopy positive malaria parasites samples during extraction.

*Pfcrt* polymorphisms {#Sec10}
---------------------

A total of 119 DNA samples were successfully tested for *Pfcrt* genotype at codons 72--76. Most of the isolates (91.6%) harboured parasites with the CVIET haplotypes. The proportion of the wild type (CVMNK) among the isolates was 4.2%, while mixed haplotype infections (CVMNK/CVIET) were found in 5 isolates (4.2%) (Table [2](#Tab2){ref-type="table"}). The Southeast Asian/South American chloroquine-resistant haplotype (SVMNT) was not seen in any of the isolates.Table 2***Pfcrt*** **haplotypes and frequency of** ***Pfmdr1*** **codons in Nigerian childrenGenenGenotype/haplotypePrevalence (%)*Pfcrt***119CVIET (mutant type)109 (91.6)Amino acids (72--76)CVMNK (wild type)5 (4.2)CVMNK/CVIET (mixed)5 (4.2)***Pfmdr1***Amino acids 86, 184, 1034, 1042 and 12467486Y (mutant type)46 (62.2)86 N (wild type)14 (18.9)86 N + 86Y (mixed)14 (18.9)71184 F (mutant type)49 (69)184Y (wild type)11 (15.5)184 F + 184Y (mixed)11 (15.5)811034C (mutant type)0(0)1034S (wild type)81(100)811042D (mutant type)0(0)1042 N (wild type)81(100)291246S (mutant type)0(0)1246D (wild type)29(100)

*Pfmdr1* polymorphisms {#Sec11}
----------------------

The isolates were genotyped for *Pfmdr1* at codons 86, 184, 1034, 1042 and 1246. The majority of isolates had the mutant *Pfmdr1* Y86 and F184 alleles. Of the isolates, 62.2% (46/74) carried the mutant allele Y86 and 69% (49/71) and had the mutant allele F184 (Table [2](#Tab2){ref-type="table"}). There was no mutation in codons 1034, 1042 and 1246 in any isolates.

Discussion {#Sec12}
==========

Self-treatment with chloroquine and other monotherapies are still high in the population because of their affordability, accessibility, and low implementation of the malaria treatment guidelines that recommends the use of ACTs. The access to, and high usage of CQ and other monotherapies in the treatment of malaria makes the determination of chloroquine resistant *Plasmodium falciparum* in Lagos imperative several years after the change in malaria treatment policy. CQ is still sold especially in the informal private sector among the Private Propriety Medicine Vendors (PPMVs), otherwise known as medicine retailers, a group that provide malaria treatment to over 60% of fever patients in the country. Further, the PPMVs sell antimalarial medicines on the basis of their clients' complaints and are not permitted to do a blood based test due to policy restrictions.

Mutations in the region of *Pfcrt* codons 72 -- 76 is said to be a key marker of *P. falciparum* chloroquine resistance \[[@CR16]\]. This study showed high prevalence of *Pfcrt* CVIET haplotype (72--76). This result is consistent with previous study where majority (98%) of the isolates genotyped carried the chloroquine resistant CVIET haplotype in Uganda \[[@CR31]\] and in Swaziland \[[@CR32]\]. Persistence of high prevalence of CVIET was also reported in Ethiopia due the continuous use of chloroquine for the treatment of *P. vivax* \[[@CR33]\]. This study showed that the SVMNT haplotype does not occur in Lagos, Nigeria. The absence of the SVMNT haplotype which is known to occur majorly in South America is consistent with many other reports in Africa \[[@CR16],[@CR32]\] except studies in part of East Africa (Tanzania and Angola)that reported SVMNT \[[@CR18],[@CR34]\]. This was presumed to be as a result of *P. falciparum* resistance to amodiaquine or its metabolite desethyl-amodiaquine following the use of amodiaquine as monotherapy.

The present study showed prevalence of 62.2% and 69.0% for *Pfmdr1* Y86 and F184 (mutant-type) respectively. The role of *Pfmdr1* gene mutations in anti-malarial drugs resistance is still controversial. An *in vivo* study where a chloroquine-resistant infection was reported showed absence of mutations at codons *Pfmdr1* 86 and 1246 in the \[[@CR35],[@CR36]\]. Similarly, a study in South-Eastern Iran reported a strong association between *pfcrt* K76T, but not *pfmdr1* N86Y mutation and *in vivo* chloroquine resistance \[[@CR37]\]. A study in Haiti reported mutation in F184 only in the *Pfmdr1* gene and no mutation was seen in *Pfcrt* gene codon 72--76 \[[@CR38]\]. In contrast, Y86 have been reported to be responsible for chloroquine resistance in combination with *Pfcrt* 76 T \[[@CR13],[@CR21],[@CR39]\] and another study from Madagascar reported an association between *Pfmdr1* Y86 mutant alleles and chloroquine clinical resistance with no such association with *Pfcrt*gene \[[@CR40]\]. Polymorphisms in the *Pfmdr1* gene have been said to be under artemether-lumenfantrine selection pressure \[[@CR41]\]. Selection of *Pfmdr1* Y86by amodiaquine and chloroquine were reported previously in the Gambia \[[@CR42]\], and in Kenya \[[@CR43]\]. Thus, the success of treatment with ACTs may largely depend on the parasite's existing level of tolerance to the partner drugs.

Some earlier studies in the pre-ACT days in South-West Nigeria reported high chloroquine-resistant parasites in children treated with CQ when CQ was the drug of choice for the treatment of malaria and they only determined mutation at position 76 (K76T). Mutation at 76 (K76T) had been reported to play a decisive role in conferring resistance to CQ \[[@CR4]\]. In a semi-urban area of Lagos, South-West Nigeria, the prevalence of T76 mutation was 74.6% \[[@CR20]\], while another study In Ibadan; South-West Nigeria reported 62% and 29% for T76 and Y86 mutations respectively \[[@CR21]\]. Prevalence of 74%, 29% and 64% were reported for mutations at T76, Y86 and F184 respectively in children with *P. falciparum* even before they were treated in Osogbo, South-West Nigeria while in another study in Ibadan (south-West Nigeria), a prevalence of 60%, 33% and 14% mutations at T76, Y86 and F184 respectively was reported in children whose age ranged from 6 month - 12 years \[[@CR44]\]. Also another study in Ogun State, still in the South-West zone of Nigeria, reported a prevalence of 96.9% at K76T among children under the age of five years \[[@CR45]\].

Our study in Lagos, South-West Nigeria, has showed the persistence of chloroquine-resistant parasites circulating in children four years after the change in policy for the treatment of uncomplicated malaria from CQ to ACTs. It is therefore important that apart from the change in policy to ACTs, there is an urgent need to restrict the use of chloroquine in the general population by the regulatory agency for drugs. Since resistant phenotypes often have fitness costs \[[@CR46]\], their prevalence is likely to decline after removal of the selective pressure. In countries where the change in policy from chloroquine to ACT was strictly enforced, marked decrease in chloroquine-resistant parasites in the population was recorded. In a recent surveillance study in Honduras, Central America, where CQ is still used for the management of uncomplicated malaria, all the samples tested showed CQ susceptibility in the *Pfcrt* "CVMNK" genotype in codons 72--76 \[[@CR47]\].

There was a decrease in the frequency of *Pfcrt*76T mutation when CQ was abolished in the treatment of *P. falciparum* malaria in the People's Republic of China \[[@CR48]\]; prevalence of mutant alleles of *Pfcrt*76T decreased from 64.5% in 2002 to 16% in 2004 and that of the mutant *Pfmdr1* 86Y alleles decreased from 46.6% to 2.7% two and half years after successful withdrawal of CQ in coastal Tanzania \[[@CR49]\]. It was also reported that the prevalence of the CQ-resistant *Pfcrt*76T genotype decreased from 85% in 1992 to 13% in 2000 in Malawi \[[@CR49]\]. In 2001, CQ cleared 100% of 63 asymptomatic *P. falciparum* infections as no isolates were resistant to CQ *in vitro*, and no infections with the CQ resistant *Pfcrt*76T genotype were detected \[[@CR50]\]. Similarly, it was shown that CQ was again an efficacious treatment for malaria, 12 years after it was successfully withdrawn from use in Malawi \[[@CR23]\]. Similar result was also reported in Kenya where the frequency of the *Pfcrt*-76 mutant significantly decreased from around 95% to 60%, though, the frequency of *Pfmdr1*-86 did not decline substantially \[[@CR24]\]. In Tanzania, where chloroquine is no longer in use, the frequency of the wild type CVMNK haplotype increased from 6% in 2003 to 30% in 2007. These findings may reflect decreasing drug pressure of chloroquine on the parasite populations in these areas.

Surveillance for antimalarial drug resistance, using the platform provided by the National Malaria control Programme in Nigeria should be supported to undertake regular and robust monitoring of malaria parasite resistance genes for trends. The use of amodiaquine has been associated to a certain extent with *Pfcrt*76T and *Pfmdr1* 86Y mutations \[[@CR21],[@CR43]\]. Furthermore, the partner drugs to ACT are also threatened by the development of resistance if treatment of malaria with antimalarial monotherapy is not abolished \[[@CR51],[@CR52]\]. Importantly, the implementation of the current malaria treatment policy using the ACTs should be strengthened, vigorously promoted, through regular training, supervision among health workers; and the institution of best procurement practices for malaria medicines at all levels based on National Policy recommendations. The regulatory agency, National Agency for Food Drug Administration and Control (NAFDAC) should regulate access to chloroquine in Nigeria while the general public should be enlightened on the high levels of circulating resistant-malaria parasite genes to chloroquine, its low efficacy and to discourage its continuous use for the for the treatment of uncomplicated malaria. Access to ACTs should be expanded and made affordable especially in the private sector where a high number of persons with fever are treated.

Conclusion {#Sec13}
==========

There is a high level of CQ-resistant-haplotypes of *P. falciparum* (CVIET) and high frequency of mutations in *Pfmdr1* four years after the change in malaria treatment policy from CQ to ACTs for the treatment of uncomplicated malaria in Lagos, South-western Nigeria. This suggests persistent circulation and spread of CQ-resistant *P. falciparum* parasites in the population and the need to strengthen current efforts at promoting ACT use in the treatment of uncomplicated malaria. The continued use of CQ for the treatment of malaria in Nigeria could be one major reason for the persistence of mutant *Pfcrt* haplotypes and *Pfmdr1* mutations in the study area. This could threaten the efficacy of partner drugs in the ACTs. Data from this study provided evidence of continued CQ use and the need for the key players in the Federal Ministry of Health to decisively regulate the use of CQ in Nigeria.
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